Browsing: Alzheimers

The FDA clearance follows European ⁠approval for the test in May. See all topics

The U.S. Food and Drug Administration (FDA) has cleared for marketing an innovative blood test with underlying technology invented at Washington University School of Medicine in St. Louis for the early diagnosis of Alzheimer’s disease. The test, known as PrecivityAD2, was developed and validated by C2N Diagnostics, a WashU startup company

An estimated 32 million people around the world are living with a type of dementia called Alzheimer’s disease

Grant cancellations at leading research institutions appear to target study of impacts of racism on brain health

A nationwide Swedish study sheds light on how blood thinners might help slow cognitive decline in people with both atrial fibrillation (AFib), an irregular heart rhythm, and Alzheimer’s disease

A study led by the Neuroimaging of Aging and Neurodegenerative Diseases research group at the Sant Pau Research Institute (IR Sant Pau) analyzed these abnormalities using a diffusion magnetic resonance imaging metric known as PSMD – short for peak width of skeletonized mean diffusivity – which can detect microscopic changes in white matter tracts that may…

It’s carnival season, and next week in Annapolis, there is a special event at a senior living community to raise money and awareness for Alzheimer’s disease

Vanderbilt Health researchers have received a grant from Eli Lilly and Company, a multinational pharmaceutical company headquartered in Indianapolis, to build an artificial intelligence (AI) tool within the electronic health record system (EHR) to get patients with Alzheimer’s disease to treatment faster. The computer project is designed for transferability to other health systems

One of the hallmarks of Alzheimer’s disease is the accumulation of a peptide in the brain known as amyloid beta. A new Nature Communications study published July 22 has uncovered the atomic structure of the peptide when it’s damaging to the brain

Researchers from VIB, KU Leuven, the UK-DRI and Muna Therapeutics, with funding that included support from ERC, have identified a major biological shift that may help determine whether Alzheimer’s disease changes in the brain eventually lead to dementia